Recent Financing Allows WellGen to Begin Studies
WellGen, Inc., New Brunswick, NJ, has completed its Series B financing totaling $3 million. The capital raised from this latest round of financing will provide the company with the additional resources it needs to begin clinical studies in humans under its Obesity and Inflammation Programs, which are aimed at developing and bringing to market a variety of new and promising nutritional products. Investors in this round of financing include both new and existing WellGen shareholders.